exhibit 10. 8 cfo service agreement between dandrit biotech a / s cvr no 26 02 73 22 c / o symbion science park fruebjergvej 3 2100 copenhagen denmark ( hereinafter referred to as the ” company ” ) and crossfield inc., robert e. wolfe po box 189 randolph, vt 05060 u. s. a. ( hereinafter referred to as the ” cfo ” ) dandrit biotech a / s cvr no 26 02 73 22 c / o symbion science park fruebjergvej 3 2100 copenhagen denmark ( hereinafter referred to as the ” company ” ) dandrit biotech a / s cvr no 26 02 73 22 c / o symbion science park fruebjergvej 3 2100 copenhagen denmark ( hereinafter referred to as the ” company ” ) dandrit biotech a / s cvr no 26 02 73 22 c / o symbion science park fruebjergvej 3 2100 copenhagen denmark ( hereinafter referred to as the ” company ” ) and and and crossfield inc., robert e. wolfe po box 189 randolph, vt 05060 u. s. a. ( hereinafter referred to as the ” cfo ” ) crossfield inc., robert e. wolfe po box 189 randolph, vt 05060 u. s. a. ( hereinafter referred to as the ” cfo ” ) crossfield inc., robert e. wolfe po box 189 randolph, vt 05060 u. s. a. ( hereinafter referred to as the ” cfo ” ) ( the company and the cfo hereinafter individually referred to as a ” party ” and collectively referred to as the ” parties ” ) background a. effective as from july 11, 2017, the cfo is to be hired as consultant and chief financial officer ( cfo ) of the company and chief financial officer ( cfo ) of the parent company ; dandrit biotech usa, inc. a. effective as from july 11, 2017, the cfo is to be hired as consultant and chief financial officer ( cfo ) of the company and chief financial officer ( cfo ) of the parent company ; dandrit biotech usa, inc. a. effective as from july 11, 2017, the